Results 1 to 10 of about 231,116 (154)

Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome

OncoImmunology, 2019
Adjuvant immunotherapies targeting CTLA4 or PD-1 recently demonstrated efficacy in the treatment of earlier stages of human cancer. We previously demonstrated using mouse spontaneous metastasis models that neoadjuvant immunotherapy and surgery was ...
Mark J. Smyth, Jason Madore, Juming Yan
exaly   +3 more sources

Progress of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2022
Neoadjuvant immunotherapy, including neoadjuvant single- or dual-drug immunotherapy or combined immunotherapy with chemotherapy or radiotherapy, has witnessed a rapid development in non-small cell lung cancer.
Chao GUO, Jiaqi ZHANG, Shanqing LI
doaj   +2 more sources

Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer [PDF]

Frontiers in Immunology, 2023
ObjectivesRecent clinical studies have demonstrated that immunotherapy-based neoadjuvant therapy have promising effectiveness for patients with resectable non-small cell lung cancer (NSCLC) in terms of pathologic response.
Jie Shen, Linping Gu, Yuwen Qi, Yaxian Yao, Shun Lu, Zhiwei Chen   +5 more
doaj   +2 more sources

Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art

Cancer Communications, 2021
Lung cancer mortality has decreased over the past decade and can be partly attributed to advances in targeted therapy and immunotherapy. Immune checkpoint inhibitors (ICIs) have rapidly evolved from investigational drugs to standard of care for the ...
Wen-Zhao Zhong, Jin Kang
exaly   +2 more sources

Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy

OncoImmunology, 2019
New clinical trials are now evaluating the efficacy of neoadjuvant immunotherapy in the context of primary tumor surgery. Using the orthotopic 4T1.2 mouse model of spontaneously metastatic mammary cancer, we have shown that neoadjuvant immunotherapy and ...
Mark J. Smyth, Lorenzo Fanchi, Elisa A Rozeman   +2 more
exaly   +2 more sources

Neoadjuvant immunotherapy in squamous cell carcinoma of the head and neck: current evidence and future perspectives

Molecular Cancer
Head and Neck Squamous Cell Carcinoma (HNSCC) is a highly aggressive malignant tumor. Traditional therapeutic approaches have limited efficacy in locally advanced HNSCC patients, and neoadjuvant immunotherapy has emerged as a new hope.
Ying Long, Haolei Tan
exaly   +2 more sources

Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC)

Frontiers in Oncology, 2023
BackgroundThe emergence of immune checkpoint inhibitors (ICIs) has brought about a paradigm shift in the treatment landscape of non-small cell lung cancer (NSCLC).
Qin Wang, Chen Qi, Jing Luo, Nan Xu, Mao-tian Xu, Yong Qiang, Chi Zhang, Yi Shen   +7 more
doaj   +1 more source

An open, observational, three-arm clinical study of 2–3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis

Frontiers in Immunology, 2022
BackgroundAn open, observational, three-arm clinical study aimed at investigating the efficacy of different neoadjuvant therapies (neoadjuvant immunotherapy with(out) chemotherapy, neoadjuvant chemotherapy, and neoadjuvant targeted therapy) in operable ...
Linping Gu, Xue Wang, Yile Sun, Yunhua Xu, Xiaomin Niu, Ruiying Zhao, Yaxian Yao, Hong Jian, Yuchen Han, Jinwang Wei, Zhiwei Chen, Shun Lu   +11 more
doaj   +1 more source

An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer

Frontiers in Oncology, 2023
BackgroundThis open, observational clinical study aimed to investigate the efficacy, safety and survival outcomes of neoadjuvant chemotherapy, neoadjuvant immunotherapy with(out) chemotherapy and neoadjuvant targeted therapy among resectable stage III ...
Yuwen Qi, Linping Gu, Jie Shen, Yaxian Yao, Yi Zhao, Shun Lu, Zhiwei Chen   +6 more
doaj   +1 more source

Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer

Frontiers in Oncology, 2023
Lung cancer is one of the leading causes of cancer-related death. Lung cancer mortality has decreased over the past decade, which is partly attributed to improved treatments.
Yurong Peng, Zhuo Li, Yucheng Fu, Yue Pan, Yue Zeng, Junqi Liu, Chaoyue Xiao, Yingzhe Zhang, Yahui Su, Guoqing Li, Fang Wu   +10 more
doaj   +1 more source